Search

Your search keyword '"Canaani, Jonathan"' showing total 13 results
Start Over Author "Canaani, Jonathan" Journal american journal of hematology
13 results on '"Canaani, Jonathan"'

2. Thiotepa‐based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched‐pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Eder, Sandra, Canaani, Jonathan, Beohou, Eric, Labopin, Myriam, Sanz, Jaime, Arcese, William, Or, Reuven, Finke, Juergen, Cortelezzi, Agostino, Beelen, Dietrich, Passweg, Jakob, Socié, Gerard, Gurman, Gunhan, Aljurf, Mahmoud, Stelljes, Matthias, Giebel, Sebastian, Mohty, Mohamad, and Nagler, Arnon

Published
2017
Full Text
View/download PDF

3. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3‐ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party / European society of blood and marrow transplantation

Author

Nagler, Arnon, primary, Labopin, Myriam, additional, Craddock, Charles, additional, Socié, Gerard, additional, Yakoub‐Agha, Ibrahim, additional, Gedde‐Dahl, Tobias, additional, Niittyvuopio, Riitta, additional, Byrne, Jennifer Louise, additional, Cornelissen, Jan J., additional, Labussière‐Wallet, Hélène, additional, Arcese, William, additional, Milpied, Noel, additional, Esteve, Jordi, additional, Canaani, Jonathan, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

4. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice

Author

Apel, Arie, primary, Moshe, Yakir, additional, Ofran, Yishai, additional, Gural, Alexander, additional, Wolach, Ofir, additional, Ganzel, Chezi, additional, Canaani, Jonathan, additional, Zektser, Miri, additional, Duek, Adrian, additional, Stemer, Galia, additional, Hellman, Ilana, additional, Basood, May, additional, Frisch, Avraham, additional, Leibovitch, Chiya, additional, and Koren‐Michowitz, Maya, additional

Published
2021
Full Text
View/download PDF

5. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3‐ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.

Author

Nagler, Arnon, Labopin, Myriam, Craddock, Charles, Socié, Gerard, Yakoub‐Agha, Ibrahim, Gedde‐Dahl, Tobias, Niittyvuopio, Riitta, Byrne, Jennifer Louise, Cornelissen, Jan J., Labussière‐Wallet, Hélène, Arcese, William, Milpied, Noel, Esteve, Jordi, Canaani, Jonathan, and Mohty, Mohamad

Published
2022
Full Text
View/download PDF

6. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation

Author

Nagler, Arnon, primary, Labopin, Myriam, additional, Canaani, Jonathan, additional, Niittyvuopio, Riitta, additional, Socié, Gerard, additional, Kröger, Nicolaus, additional, Itäla‐Remes, Maija, additional, Yakoub‐Agha, Ibrahim, additional, Labussière‐Wallet, Hélène, additional, Gallego‐Hernanz, Maria P., additional, Deconinck, Eric, additional, Chevallier, Patrice, additional, Finke, Jürgen, additional, Esteve, Jordi, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

7. T‐cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3‐ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Canaani, Jonathan, primary, Labopin, Myriam, additional, Huang, Xiao‐Jun, additional, Arcese, William, additional, Ciceri, Fabio, additional, Blaise, Didier, additional, Irrera, Giuseppe, additional, Corral, Lucia Lopez, additional, Bruno, Benedetto, additional, Santarone, Stella, additional, Van Lint, Maria Teresa, additional, Vitek, Antonin, additional, Esteve, Jordi, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

8. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation

Author

Canaani, Jonathan, primary, Savani, Bipin N., additional, Labopin, Myriam, additional, Huang, Xiao‐Jun, additional, Ciceri, Fabio, additional, Arcese, William, additional, Koc, Yener, additional, Tischer, Johanna, additional, Blaise, Didier, additional, Gülbas, Zafer, additional, Van Lint, Maria Teresa, additional, Bruno, Benedetto, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

9. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT

Author

Canaani, Jonathan, primary, Savani, Bipin N., additional, Labopin, Myriam, additional, Michallet, Mauricette, additional, Craddock, Charles, additional, Socié, Gerard, additional, Volin, Lisa, additional, Maertens, Johan A., additional, Crawley, Charles, additional, Blaise, Didier, additional, Ljungman, Per T., additional, Cornelissen, Jan, additional, Russell, Nigel, additional, Baron, Frédéric, additional, Gorin, Norbert, additional, Esteve, Jordi, additional, Ciceri, Fabio, additional, Schmid, Christoph, additional, Giebel, Sebastian, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

10. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT

Author

Canaani, Jonathan, primary, Labopin, Myriam, additional, Socié, Gerard, additional, Nihtinen, Anne, additional, Huynh, Anne, additional, Cornelissen, Jan, additional, Deconinck, Eric, additional, Gedde-Dahl, Tobias, additional, Forcade, Edouard, additional, Chevallier, Patrice, additional, Bourhis, Jean H., additional, Blaise, Didier, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

11. Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT

Author

Canaani, Jonathan, primary, Beohou, Eric, additional, Labopin, Myriam, additional, Socié, Gerard, additional, Huynh, Anne, additional, Volin, Liisa, additional, Cornelissen, Jan, additional, Milpied, Noel, additional, Gedde-Dahl, Tobias, additional, Deconinck, Eric, additional, Fegueux, Nathalie, additional, Blaise, Didier, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

12. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation

Author

Johanna Tischer, Myriam Labopin, Arnon Nagler, Yener Koc, Xiao-Jun Huang, Fabio Ciceri, William Arcese, Benedetto Bruno, Maria Teresa Van Lint, Bipin N. Savani, Jonathan Canaani, Mohamad Mohty, Didier Blaise, Zafer Gulbas, Service d’Hématologie [Institut Paoli Calmettes, Marseille], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Canaani, Jonathan, Savani, Bipin N, Labopin, Myriam, Huang, Xiao-Jun, Ciceri, Fabio, Arcese, William, Koc, Yener, Tischer, Johanna, Blaise, Didier, Gülbas, Zafer, Van Lint, Maria Teresa, Bruno, Benedetto, Mohty, Mohamad, and Nagler, Arnon

Subjects
Adult, Male, medicine.medical_specialty, haploidentical hematopoietic cell transplantation, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Acute Disease, Age Factors, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Middle Aged, Registries, Retrospective Studies, Survival Analysis, Transplantation, Haploidentical, Treatment Outcome, Unrelated Donors, acute lymphoblastic leukemia, Hematopoietic stem cell transplantation, Haploidentical, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, Survival analysis, Transplantation, Acute leukemia, Acute myeloid leukemia, business.industry, Donor selection, Hazard ratio, Myeloid leukemia, Hematology, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, business, Settore MED/15 - Malattie del Sangue, 030215 immunology
Abstract

Haploidentical hematopoietic cell transplantation (haplo-HCT) is being increasingly used in acute leukemia patients as an alternative transplant modality when matched sibling or matched unrelated donors are unavailable. As several potential haploidentical relative donors are typically available for a given patient, optimizing donor selection to improve clinical outcome is crucial. The impact of donor age and kinship on the outcome of acute leukemia patients is not clearly established in this setting. Using the multinational registry of the acute leukemia working party of the European society for blood and marrow transplantation we retrospective analyzed the clinical outcome of 1270 acute myeloid leukemia and acute lymphoblastic leukemia patients who underwent haplo-HCT between 2005 and 2015. Patients over the age of 40 were significantly affected by increasing donor age resulting in higher non-relapse mortality (NRM) [Hazard ratio (HR)=1.86, confidence interval (CI) 95%, 1.18-2.94; P = .007], inferior leukemia-free survival (LFS) (HR = 1.59, CI 95%, 1.13-2.24; P = .007), and overall survival (OS) (HR = 1.74, CI 95%, 1.22-2.47; P = .002) when donors were over the age of 40. Additionally, kinship was found to be prognostically significant as patients transplanted from children donors over the age of 35 experienced an increased rate of NRM (HR = 1.82, CI 95%, 1.13-2.9; P = .01), inferior LFS (HR = 1.5, CI 95%, 1.05-2.13; P = .03), and OS (HR = 1.5, CI 95%, 1.04-2.15; P = .03). For patients younger than 40 years, donor age and kinship were mostly not clinically impactful. Our data establish donor age and kinship as significant determinants of outcome following haplo-HCT for acute leukemia patients.

Published
2017

13. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT

Author

Fabio Ciceri, Nigel H. Russell, Mauricette Michallet, Sebastian Giebel, Liisa Volin, Myriam Labopin, Per Ljungman, Christoph Schmid, Johan Maertens, Jordi Esteve, Jonathan Canaani, Charles Craddock, Norbert Claude Gorin, Bipin N. Savani, Arnon Nagler, Mohamad Mohty, Charles Crawley, Gérard Socié, Jan J. Cornelissen, Didier Blaise, Frédéric Baron, Hematology, Canaani, Jonathan, Savani, Bipin N., Labopin, Myriam, Michallet, Mauricette, Craddock, Charle, Sociã©, Gerard, Volin, Lisa, Maertens, Johan A., Crawley, Charle, Blaise, Didier, Ljungman, Per T., Cornelissen, Jan, Russell, Nigel, Baron, Frã©dã©ric, Gorin, Norbert, Esteve, Jordi, Ciceri, Fabio, Schmid, Christoph, Giebel, Sebastian, Mohty, Mohamad, Nagler, Arnon, Clinicum, Hematologian yksikkö, Department of Oncology, and HUS Comprehensive Cancer Center

Subjects
Male, Transplantation Conditioning, IMPACT, Graft vs Host Disease, Gastroenterology, HEMATOLOGIC MALIGNANCIES, 0302 clinical medicine, Retrospective Studie, HLA Antigens, hemic and lymphatic diseases, VERSUS-HOST-DISEASE, HLA Antigen, Transplantation, Homologou, OUTCOMES, Acute leukemia, Incidence (epidemiology), Hazard ratio, Graft Survival, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Hematology, Middle Aged, 3. Good health, Leukemia, Myeloid, Acute, Treatment Outcome, 030220 oncology & carcinogenesis, Blood Group Incompatibility, Female, Survival Analysi, Unrelated Donors, Human, Adult, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Adolescent, 3122 Cancers, 03 medical and health sciences, Young Adult, ABO blood group system, Internal medicine, parasitic diseases, medicine, Humans, Transplantation, Homologous, Aged, Retrospective Studies, Unrelated Donor, business.industry, MORTALITY, CORD BLOOD TRANSPLANTATION, medicine.disease, BONE-MARROW-TRANSPLANTATION, COMPATIBILITY, Survival Analysis, biological factors, Confidence interval, Transplantation, RECIPIENTS, Graft-versus-host disease, 3121 General medicine, internal medicine and other clinical medicine, Immunology, RISK-FACTORS, business, 030215 immunology
Abstract

ABO incompatibility is commonly observed in stem cell transplantation and its impact in this setting has been extensively investigated. HLA-mismatched unrelated donors (MMURD) are often used as an alternative stem cell source but are associated with increased transplant related complications. Whether ABO incompatibility affects outcome in MMURD transplantation for acute myeloid leukemia (AML) patients is unknown. We evaluated 1,013 AML patients who underwent MMURD transplantation between 2005 and 2014. Engraftment rates were comparable between ABO matched and mismatched patients, as were relapse incidence [34%; 95% confidence interval (CI), 28-39; for ABO matched vs. 36%; 95% CI, 32-40; for ABO mismatched; P = .32], and nonrelapse mortality (28%; 95% CI, 23-33; for ABO matched vs. 25%; 95% CI, 21-29; for ABO mismatched; P = .2). Three year survival was 40% for ABO matched and 43% for ABO mismatched patients (P = .35), Leukemia free survival rates were also comparable between groups (37%; 95% CI, 32-43; for ABO matched vs. 38%; 95% CI, 33-42; for ABO mismatched; P = .87). Incidence of grade II-IV acute graft versus host disease was marginally lower in patients with major ABO mismatching (Hazard ratio of 0.7, 95% CI, 0.5-1; P = .049]. ABO incompatibility probably has no significant clinical implications in MMURD transplantation. ispartof: American Journal of Hematology vol:92 issue:8 pages:789-796 ispartof: location:United States status: published

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results